Skip Navigation

JNCI Journal of the National Cancer Institute 2002 94(8):631-632; doi:10.1093/jnci/94.8.631
© 2002 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Rebbeck, T. R.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Rebbeck, T. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 94, No. 8, 631-632, April 17, 2002
© 2002 Oxford University Press

CORRESPONDENCE

RESPONSE:

Timothy R. Rebbeck

Correspondence to: Timothy Rebbeck, Ph.D., University of Pennsylvania School of Medicine, Department of Biostatistics and Epidemiology, 904 Blockley Hall, 423 Guardian Dr., Philadelphia, PA 19104–6021 (e-mail: trebbeck@cceb.med.upenn.edu).

Wojnowski et al. provide a welcome and provocative insight into the conflicting data regarding the functional relevance of CYP3A4*1B and its effect on disease endpoints. As these authors suggest, two explanations are commonly given when a genotype–disease association is observed. First, the allele under study may be in . . . [Full Text of this Article]

REFERENCES


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
A. L. Beitelshees and H. L. McLeod
Clopidogrel pharmacogenetics: promising steps towards patient care?
Arterioscler Thromb Vasc Biol, August 1, 2006; 26(8): 1681 - 1683.
[Full Text] [PDF]